Fennec Pharmaceuticals sells PEDMARK, the only FDA-approved drug to reduce the risk of hearing loss from cisplatin chemotherapy in children with localized solid tumors.
Fennec's case rests on PEDMARK, the only FDA-approved drug to reduce cisplatin-related hearing loss in children with localized solid tumors. Net product sales reached $17.2 million in the second quarter, up 78% from a year earlier, and Fennec earned $2.2 million in the first half. A settlement keeps Cipla's generic off the market until September 2033, or earlier in certain circumstances. Further growth depends on wider U.S. use, including young adults, Norgine's European sales and a Japan partner. Cash was $41.2 million at June 30.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: PEDMARK U.S. sales keep growing
Do PEDMARK sales keep growing from the second quarter's $17.2 million while Fennec stays profitable?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
PEDMARK sales rose 78% in the second quarter, and Fennec is now profitable
PEDMARK's commercial trajectory and 2033 generic exclusivity define whether Fennec can compound a niche pediatric otoprotection franchise into durable value
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
1 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.